UK markets open in 7 hours 56 minutes

Scancell Holdings plc (SCLP.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
12.25-1.45 (-10.58%)
At close: 04:25PM GMT

Scancell Holdings plc

Bellhouse Building
Unit 202 Sanders Road Oxford Science Park
Oxford OX4 4GD
United Kingdom
44 18 6558 2066
https://www.scancell.co.uk

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees51

Key executives

NameTitlePayExercisedYear born
Prof. Lindy Gillian Durrant Ph.D.Founder, CEO, Chief Scientific Officer & Director369.12kN/A1957
Dr. Sally Elizabeth AdamsChief Development Officer & Director253.51kN/A1961
Mr. Sathijeevan NirmalananthanChief Financial OfficerN/AN/AN/A
Dr. Samantha Paston Ph.D.Head of Translational ResearchN/AN/AN/A
Dr. Adrian Parry Ph.D.Head of ManufacturingN/AN/AN/A
Ms. Akua AsareHead of QualityN/AN/AN/A
Dr. Mandeep SehmiHead of Business DevelopmentN/AN/AN/A
Mr. Keith Charles GreenCompany SecretaryN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clinical trials for the treatment of solid tumors including triple negative breast, ovarian, renal, and head and neck cancers; and Modi-2, which targets homocitrullinated cancer antigens. In addition, the company focuses to develop SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

Corporate governance

Scancell Holdings plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.